Corrigendum to ‟Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulationsˮ [Inform. Med. Unlocked 23 (2021) 1-9/100541]

Detalles Bibliográficos
Autores principales: Mahdian, Soodeh, Zarrabi, Mahboobeh, Panahi, Yunes, Dabbagh Sadeghpour, Somayyeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158040/
https://www.ncbi.nlm.nih.gov/pubmed/37362152
http://dx.doi.org/10.1016/j.imu.2023.101263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158040/
https://www.ncbi.nlm.nih.gov/pubmed/37362152
http://dx.doi.org/10.1016/j.imu.2023.101263

Ejemplares similares